Organovo (ONVO) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONVO vs. MEIP, PRPH, GELS, ME, RLMD, TRIB, SYBX, ERNA, MRKR, and CLDIShould you be buying Organovo stock or one of its competitors? The main competitors of Organovo include MEI Pharma (MEIP), ProPhase Labs (PRPH), Gelteq (GELS), 23andMe (ME), Relmada Therapeutics (RLMD), Trinity Biotech (TRIB), Synlogic (SYBX), Eterna Therapeutics (ERNA), Marker Therapeutics (MRKR), and Calidi Biotherapeutics (CLDI). These companies are all part of the "pharmaceutical products" industry. Organovo vs. MEI Pharma ProPhase Labs Gelteq 23andMe Relmada Therapeutics Trinity Biotech Synlogic Eterna Therapeutics Marker Therapeutics Calidi Biotherapeutics MEI Pharma (NASDAQ:MEIP) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings. Does the MarketBeat Community favor MEIP or ONVO? MEI Pharma received 227 more outperform votes than Organovo when rated by MarketBeat users. Likewise, 63.32% of users gave MEI Pharma an outperform vote while only 45.37% of users gave Organovo an outperform vote. CompanyUnderperformOutperformMEI PharmaOutperform Votes42363.32% Underperform Votes24536.68% OrganovoOutperform Votes19645.37% Underperform Votes23654.63% Does the media prefer MEIP or ONVO? In the previous week, Organovo had 2 more articles in the media than MEI Pharma. MarketBeat recorded 2 mentions for Organovo and 0 mentions for MEI Pharma. MEI Pharma's average media sentiment score of 0.00 beat Organovo's score of -0.10 indicating that MEI Pharma is being referred to more favorably in the media. Company Overall Sentiment MEI Pharma Neutral Organovo Neutral Do insiders and institutionals believe in MEIP or ONVO? 52.4% of MEI Pharma shares are owned by institutional investors. Comparatively, 8.2% of Organovo shares are owned by institutional investors. 3.1% of MEI Pharma shares are owned by insiders. Comparatively, 3.7% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer MEIP or ONVO? Given Organovo's higher probable upside, analysts clearly believe Organovo is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MEI Pharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Organovo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is MEIP or ONVO more profitable? MEI Pharma has a net margin of 0.00% compared to Organovo's net margin of -10,151.64%. MEI Pharma's return on equity of -84.92% beat Organovo's return on equity.Company Net Margins Return on Equity Return on Assets MEI PharmaN/A -84.92% -67.53% Organovo -10,151.64%-346.26%-187.53% Which has more risk and volatility, MEIP or ONVO? MEI Pharma has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Organovo has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Which has higher earnings & valuation, MEIP or ONVO? MEI Pharma has higher revenue and earnings than Organovo. MEI Pharma is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMEI Pharma$65.30M0.22$17.78M-$4.75-0.45Organovo$122K0.00-$14.67M-$10.20N/A SummaryMEI Pharma beats Organovo on 12 of the 16 factors compared between the two stocks. Get Organovo News Delivered to You Automatically Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONVO vs. The Competition Export to ExcelMetricOrganovoBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.47M$2.93B$5.33B$8.39BDividend YieldN/A1.63%5.21%4.10%P/E Ratio-2.4031.1826.7519.70Price / SalesN/A398.78392.04122.35Price / CashN/A168.6838.2534.62Price / BookN/A3.236.774.50Net Income-$14.67M-$72.35M$3.23B$248.22M Organovo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONVOOrganovoN/AN/AN/AN/A$3.47M$122,000.00-2.4020Upcoming EarningsGap UpMEIPMEI Pharma2.1836 of 5 stars$2.08+1.3%N/A-31.0%$13.83M$65.30M-0.36100PRPHProPhase Labs1.8261 of 5 stars$0.33+7.9%N/A-94.1%$13.69M$6.77M-0.26130Earnings ReportGap DownGELSGelteqN/A$1.44+5.1%N/AN/A$13.59MN/A0.00N/APositive NewsME23andMeN/A$0.50-35.3%N/A-95.2%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeRLMDRelmada Therapeutics4.4302 of 5 stars$0.40-4.6%$4.25+962.5%-80.1%$13.28MN/A-0.1410Positive NewsInsider TradeGap DownTRIBTrinity Biotech0.7127 of 5 stars$0.73-3.1%N/A-52.6%$13.18M$59.13M-0.32480Gap DownSYBXSynlogicN/A$1.13+0.9%N/A-30.4%$13.10M$8,000.00-0.2780Gap UpHigh Trading VolumeERNAEterna Therapeutics0.7563 of 5 stars$0.21+5.2%N/A-88.5%$13.10M$582,000.00-0.0310Gap UpMRKRMarker Therapeutics4.0871 of 5 stars$1.14-1.7%$13.17+1,055.0%-71.3%$12.90M$6.59M-0.9560Positive NewsCLDICalidi Biotherapeutics1.9147 of 5 stars$0.44-3.3%$15.00+3,279.9%N/A$12.63M$50,000.000.0038Gap Down Related Companies and Tools Related Companies MEI Pharma Competitors ProPhase Labs Competitors Gelteq Competitors 23andMe Competitors Relmada Therapeutics Competitors Trinity Biotech Competitors Synlogic Competitors Eterna Therapeutics Competitors Marker Therapeutics Competitors Calidi Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONVO) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONVO Stock Free ONVO Stock Alerts